{"id":169548,"date":"2025-07-30T07:49:40","date_gmt":"2025-07-30T11:49:40","guid":{"rendered":"https:\/\/44.250.171.167\/?p=169548"},"modified":"2025-07-30T07:49:40","modified_gmt":"2025-07-30T11:49:40","slug":"strides-pharma-science-ltd-q1-fy26-earnings-results-97-fall-in-profits","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/strides-pharma-science-ltd-q1-fy26-earnings-results-97-fall-in-profits\/","title":{"rendered":"Strides Pharma Science Ltd Q1 FY26 Earnings Results &#8211; 97% fall in Profits"},"content":{"rendered":"<p>Strides Pharma Science Ltd is in the business of development and manufacturing of pharmaceutical products. The company&#8217;s pharmaceutical products are sold in over 100 countries. The company has always followed an inorganic growth strategy over the years that resulted in foray into new markets, addition of new business segments, therapy segments and manufacturing infrastructure.<\/p>\n<h2 class=\"mb-xs mt-5 text-base font-[500] first:mt-0 dark:font-[475]\">Q1 FY26 Earnings Summary<\/h2>\n<ul class=\"marker:text-textOff list-disc\">\n<li>\n<p class=\"my-0\"><strong>Revenue:<\/strong> \u20b91,119.7 crore, up 6.2% year-over-year (YoY) from \u20b91,054.3 crore in Q1 FY25 but down 5.9% quarter-over-quarter (QoQ) from \u20b91,190.4 crore in Q4 FY25.<\/p>\n<\/li>\n<li>\n<p class=\"my-0\"><strong>Gross Margin:<\/strong>\u00a0\u20b9675.5 crore, increased 11.7% YoY; gross margin percentage improved by 300 basis points YoY to 60.3%.<\/p>\n<\/li>\n<li>\n<p class=\"my-0\"><strong>EBITDA:<\/strong>\u00a0\u20b9218.1 crore, up 14.8% YoY; EBITDA margin expanded by 150 basis points to 19.5%.<\/p>\n<\/li>\n<li>\n<p class=\"my-0\"><strong>Operational Profit After Tax (PAT):<\/strong>\u00a0\u20b9114 crore, a strong 80.6% increase YoY (Q1 FY25: \u20b963.1 crore).<\/p>\n<\/li>\n<li>\n<p class=\"my-0\"><strong>Reported PAT:<\/strong> \u20b9105.6 crore, up 97% on YOY basis.<\/p>\n<\/li>\n<li>\n<p class=\"my-0\"><strong>Operational EPS:<\/strong>\u00a0\u20b912.4, up significantly from \u20b96.9 in Q1 FY25.<\/p>\n<\/li>\n<li>\n<p class=\"my-0\"><strong>US Revenue:<\/strong>\u00a0$71 million, up 7% YoY, driven by base business growth, with 70 commercialized products and continued strong market share.<\/p>\n<\/li>\n<li>\n<p class=\"my-0\"><strong>Product Approvals:<\/strong>\u00a0Received 1 product approval and launched 1 product in the US in Q1 FY26; discontinued 4 low-margin products.<\/p>\n<\/li>\n<li>\n<p class=\"my-0\"><strong>Other Markets:<\/strong>\u00a0Growth markets (including Africa, LATAM, MENA, APAC) posted \u20b9140.2 crore ($16.4 million) revenue, up 32.2% YoY. Access markets declined sharply due to donor funding challenges.<\/p>\n<\/li>\n<li>\n<p class=\"my-0\"><strong>Operating Costs:<\/strong>\u00a0Personnel cost at \u20b9225.5 crore; other operating expenses at \u20b9231.9 crore.<\/p>\n<\/li>\n<\/ul>\n<h3 class=\"mb-xs mt-5 text-base font-[500] first:mt-0 dark:font-[475]\">Key Management Commentary &amp; Strategic Highlights<\/h3>\n<ul class=\"marker:text-textOff list-disc\">\n<li>\n<p class=\"my-0\">Management emphasized <a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachLive\/33ebd29e-37e3-4ccf-a60a-57710ecbdd0b.pdf\" target=\"_blank\" rel=\"noopener\">strong margin expansion<\/a> and improved profitability due to disciplined cost control and execution.<\/p>\n<\/li>\n<li>\n<p class=\"my-0\">Focus on portfolio maximization and channel expansion in growth markets.<\/p>\n<\/li>\n<li>\n<p class=\"my-0\">Despite challenges in access markets due to reduced donor funding, the company is investing in regulatory filings and market development to stabilize growth over the next two years.<\/p>\n<\/li>\n<li>\n<p class=\"my-0\">Reiterated <a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachLive\/33ebd29e-37e3-4ccf-a60a-57710ecbdd0b.pdf\" target=\"_blank\" rel=\"noopener\">US business revenue target of ~$400 million<\/a> by FY27-28, supported by over 230 ANDA filings and 215+ approvals, with 60 dormant ANDAs in process for relaunch.<\/p>\n<\/li>\n<li>\n<p class=\"my-0\">Invested in &#8220;Beyond Generics&#8221; segments including control substances, nasal sprays to diversify growth streams.<\/p>\n<\/li>\n<li>\n<p class=\"my-0\">Continues to lead in several generic markets with top 3 position in 37 products.<\/p>\n<\/li>\n<li>\n<p class=\"my-0\">Operational discipline and cost rationalization remain key priorities.<\/p>\n<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-large wp-image-169549\" src=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/3-13-839x1024.png\" alt=\"\" width=\"640\" height=\"781\" srcset=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/3-13-839x1024.png 839w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/3-13-246x300.png 246w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/3-13-768x937.png 768w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/3-13-1259x1536.png 1259w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/3-13.png 1489w\" sizes=\"auto, (max-width: 640px) 100vw, 640px\" \/><\/p>\n<p>&nbsp;<\/p>\n<h2 class=\"mb-xs mt-5 text-base font-[500] first:mt-0 dark:font-[475]\">Q4 FY25 Earnings Summary<\/h2>\n<ul class=\"marker:text-textOff list-disc\">\n<li>\n<p class=\"my-0\"><strong>Revenue:<\/strong>\u00a0\u20b91,190.4 crore, up 17.0% year-over-year (YoY).<\/p>\n<\/li>\n<li>\n<p class=\"my-0\"><strong>Gross Margin:<\/strong>\u00a0\u20b9691.4 crore, increased 18.1% YoY, with a margin around 58.1%.<\/p>\n<\/li>\n<li>\n<p class=\"my-0\"><strong>EBITDA:<\/strong>\u00a0\u20b9217.9 crore, up 22.0% YoY; EBITDA margin expanded to 18.3%, up 75 basis points YoY.<\/p>\n<\/li>\n<li>\n<p class=\"my-0\"><strong>US Revenue:<\/strong>\u00a0$77 million, up 23.2% YoY.<\/p>\n<\/li>\n<li>\n<p class=\"my-0\"><strong>Operational Profit After Tax (PAT):<\/strong>\u00a0\u20b9113 crore, a 5-fold increase YoY.<\/p>\n<\/li>\n<li>\n<p class=\"my-0\"><strong>Operational EPS:<\/strong>\u00a0\u20b912.3, up 5 times YoY.<\/p>\n<\/li>\n<li>\n<p class=\"my-0\"><strong>Net Debt:<\/strong>\u00a0Reduced by \u20b9512.8 crore leading to an improved net debt-to-EBITDA ratio of 1.9x.<\/p>\n<\/li>\n<li>\n<p class=\"my-0\"><strong>Dividend:<\/strong>\u00a0The Board recommended a dividend of \u20b94 per share for FY25.<\/p>\n<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Strides Pharma Science Ltd is in the business of development and manufacturing of pharmaceutical products. The company&#8217;s pharmaceutical products are sold in over 100 countries. The company has always followed an inorganic growth strategy over the years that resulted in foray into new markets, addition of new business segments, therapy segments and manufacturing infrastructure. Q1 [&hellip;]<\/p>\n","protected":false},"author":1863,"featured_media":169549,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[105,5747],"tags":[10162,11793],"class_list":["post-169548","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-infographics","category-healthcare-stocks","tag-pharmaceutical","tag-pharmaceutical-research"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/3-13.png","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":169622,"url":"https:\/\/alphastreet.com\/india\/sun-pharmaceutical-industries-ltd-q1-fy26-earnings-results-20-fall-in-profits\/","url_meta":{"origin":169548,"position":0},"title":"Sun Pharmaceutical Industries Ltd Q1 FY26 Earnings Results &#8211; 20% fall in Profits","author":"Chirag Gupta","date":"July 31, 2025","format":false,"excerpt":"Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Sun Pharma Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/6-5.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/6-5.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/6-5.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/6-5.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/6-5.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/6-5.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":172176,"url":"https:\/\/alphastreet.com\/india\/solara-active-pharma-q2-fy26-earnings-results\/","url_meta":{"origin":169548,"position":1},"title":"Solara Active Pharma Q2 FY26 Earnings Results","author":"Chirag Gupta","date":"November 6, 2025","format":false,"excerpt":"Solara Active Pharma Sciences Ltd is engaged in business of manufacturing, production, processing, formulating, sale, import, export, merchandising, distributing, trading of APIs. \u00a0 Q2 FY26 Earnings Results: Revenue from Operations: \u20b9314 crore, down 9.6% YoY and 1.9% QoQ from \u20b9320 crore in Q1 FY26. Net Loss: \u20b910.1 crore, reversing from\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Solara Active Pharma Q2 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Solara-Active-Pharma-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Solara-Active-Pharma-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Solara-Active-Pharma-Q2-FY26-Earnings-Results.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Solara-Active-Pharma-Q2-FY26-Earnings-Results.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Solara-Active-Pharma-Q2-FY26-Earnings-Results.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Solara-Active-Pharma-Q2-FY26-Earnings-Results.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":169792,"url":"https:\/\/alphastreet.com\/india\/lupin-ltd-q1-fy26-earnings-results-51-rise-in-profits\/","url_meta":{"origin":169548,"position":2},"title":"Lupin Ltd Q1 FY26 Earnings Results &#8211; 51% rise in Profits","author":"Chirag Gupta","date":"August 6, 2025","format":false,"excerpt":"Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Lupin Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/1-4.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/1-4.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/1-4.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/1-4.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/1-4.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/1-4.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":170225,"url":"https:\/\/alphastreet.com\/india\/supriya-lifescience-q1-fy26-earnings-results\/","url_meta":{"origin":169548,"position":3},"title":"Supriya Lifescience Q1 FY26 Earnings Results\u00a0","author":"Chirag Gupta","date":"August 15, 2025","format":false,"excerpt":"Supriya Lifescience is engaged in the manufacturing of Active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic. Syntec Do Brasil LTDA, American International Chemical Inc. and AT Planejamento E Desenvolvimento De\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Supriya Lifescience Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/4-10.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/4-10.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/4-10.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/4-10.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/4-10.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/4-10.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":172155,"url":"https:\/\/alphastreet.com\/india\/sun-pharma-q2-fy26-earnings-results\/","url_meta":{"origin":169548,"position":4},"title":"Sun Pharma Q2 FY26 Earnings Results","author":"Chirag Gupta","date":"November 5, 2025","format":false,"excerpt":"Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Sun Pharma Q2 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Sun-Pharma-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Sun-Pharma-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Sun-Pharma-Q2-FY26-Earnings-Results.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Sun-Pharma-Q2-FY26-Earnings-Results.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Sun-Pharma-Q2-FY26-Earnings-Results.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Sun-Pharma-Q2-FY26-Earnings-Results.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":170918,"url":"https:\/\/alphastreet.com\/india\/blue-jet-healthcare-q1-fy26-earnings-results\/","url_meta":{"origin":169548,"position":5},"title":"Blue Jet Healthcare Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"September 4, 2025","format":false,"excerpt":"Blue Jet Healthcare Ltd, incorporated in 1968 (formerly Jet Chemicals Pvt Ltd), is a prominent pharmaceutical and healthcare ingredients company in India and was the first manufacturer of saccharin and its salts (artificial sweeteners) in the country. The company operates in multiple segments including contrast media intermediates, high-intensity sweeteners, and\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"BLUEJET Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/BLUEJET.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/BLUEJET.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/BLUEJET.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/BLUEJET.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/BLUEJET.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/BLUEJET.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/169548","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1863"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=169548"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/169548\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/169549"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=169548"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=169548"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=169548"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}